- Home
- BEPC vs NUVL Comparison
BEPC vs NUVL Comparison
Compare BEPC & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEPC
- NUVL
- Stock Information
- Founded
- BEPC 2019
- NUVL 2017
- Country
- BEPC United States
- NUVL United States
- Employees
- BEPC N/A
- NUVL N/A
- Industry
- BEPC Electric Utilities: Central
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- BEPC Utilities
- NUVL Health Care
- Exchange
- BEPC Nasdaq
- NUVL Nasdaq
- Market Cap
- BEPC 6.1B
- NUVL 5.8B
- IPO Year
- BEPC N/A
- NUVL 2021
- Fundamental
- Price
- BEPC $33.44
- NUVL $76.04
- Analyst Decision
- BEPC Buy
- NUVL Strong Buy
- Analyst Count
- BEPC 3
- NUVL 10
- Target Price
- BEPC $33.67
- NUVL $119.60
- AVG Volume (30 Days)
- BEPC 811.2K
- NUVL 503.8K
- Earning Date
- BEPC 08-01-2025
- NUVL 08-07-2025
- Dividend Yield
- BEPC 4.46%
- NUVL N/A
- EPS Growth
- BEPC N/A
- NUVL N/A
- EPS
- BEPC N/A
- NUVL N/A
- Revenue
- BEPC $3,882,000,000.00
- NUVL N/A
- Revenue This Year
- BEPC $42.90
- NUVL N/A
- Revenue Next Year
- BEPC $6.57
- NUVL N/A
- P/E Ratio
- BEPC N/A
- NUVL N/A
- Revenue Growth
- BEPC N/A
- NUVL N/A
- 52 Week Low
- BEPC $23.73
- NUVL $55.54
- 52 Week High
- BEPC $37.00
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- BEPC 44.41
- NUVL 44.51
- Support Level
- BEPC $32.99
- NUVL $71.13
- Resistance Level
- BEPC $33.82
- NUVL $79.00
- Average True Range (ATR)
- BEPC 0.87
- NUVL 2.98
- MACD
- BEPC -0.35
- NUVL -0.25
- Stochastic Oscillator
- BEPC 16.11
- NUVL 39.71
About BEPC Brookfield Renewable Corporation
Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia, and totals over 40 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners LP and Brookfield Renewable Corp.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.